secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001171843-26-001046
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Phase 3 paridiprubart cut 28-day mortality by 27% (p<0.001); 278-patient study positive
--------------------------------------------------------------------------------

- Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
- Consistent benefit across severity groups: 35% reduction in non-IMV (n=174) and across comorbidities (sepsis, AKI, pneumonia).
- Safety profile favorable; adverse events low and similar to placebo; over 400 patients now exposed.
- Company filed provisional patent applications for paridiprubart in sepsis, acute kidney injury, and pneumonia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326001046/0001171843-26-001046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326001046/f8k_021926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer